Bilimsel çalışmalar

Prof. Dr. Meral Beksaç

911 yayın. Her yayının yanında bilginin kaynağı yazar.

Profile dön

  1. P-038: Postinduction minimal residual disease (MRD) within stem cell graft (gMRD) correlates with marrow MRD (mMRD) and progression free survival (PFS) following autologous stem cell transplantation

    Clinical Lymphoma Myeloma & Leukemia, 2021

    DOI 10.1016/s2152-2650(21)02172-8 Kaynak: OpenAlex

  2. Poster: MM-130: Updates from ICARIA-MM, a Phase 3 Study of Isatuximab (Isa) Plus Pomalidomide and Low-Dose Dexamethasone (Pd) vs Pd in Relapsed and Refractory Multiple Myeloma (RRMM)

    Clinical Lymphoma Myeloma & Leukemia, 2021

    DOI 10.1016/s2152-2650(21)01572-x Kaynak: OpenAlex

  3. Early Access Program Results From Turkey and a Literature Review on Daratumumab Monotherapy Among Heavily Pretreated Patients With Relapsed/Refractory Myeloma

    Clinical Lymphoma Myeloma & Leukemia, 2020

    DOI 10.1016/j.clml.2020.02.017 PMID 32482539 6 atıf (Europe PMC) Açık erişimli tam metinKaynak: OpenAlex

  4. Ibrutinib As a Promising Treatment for Heavily Pretreated Waldenström Macroglobulinemia: A Real World Data

    Blood, 2020

    DOI 10.1182/blood-2020-138899 Kaynak: OpenAlex

  5. Bir Nakil Merkezinin 11 Yıllık Allojeneik Kök Hücre Nakli Deneyimi

    LLM Dergi, 2020

    DOI 10.5578/llm.70231 Açık erişimli tam metinKaynak: ORCID

  6. Miyelodisplastik Sendrom Hastalarının Akan Hücre Ölçer ile Yapılan Ogata Skorlaması Yoluyla Değerlendirilmesi: Pilot Çalışma

    LLM Dergi, 2020

    DOI 10.5578/llm.70136 Açık erişimli tam metinKaynak: ORCID

  7. Allogeneic Stem Cell Transplantation in Myelodysplastic Syndrome

    Journal of Ankara University Faculty of Medicine, 2020

    DOI 10.4274/atfm.galenos.2020.65365 Açık erişimli tam metinKaynak: ORCID

  8. 25 Years of Autologous Transplantation for Myeloma in Ebmt Centres - Changing Practice Patterns

    Bone Marrow Transplantation, 2020

    Kaynak: ORCID

  9. A Phase 3 Randomized, Open-Label, Multicenter Study Comparing Isatuximab, Pomalidomide, and Low-Dose Dexamethasone Versus Pomalidomide and Low-Dose Dexamethasone in Patients with Relapsed / Multiple Myeloma Refractory (RRMM)

    Oncology Research and Treatment, 2020

    Kaynak: ORCID

  10. A real world multicenter retrospective study on extramedullary disease from Balkan Myeloma Study Group and Barcelona University: Analysis of parameters that improve outcome

    Haematologica, 2020

    DOI 10.3324/haematol.2019.219295 PMID 31278209 65 atıf (Europe PMC) Açık erişimli tam metinKaynak: ORCID

  11. A real-world single-center retrospective study on efficacy and safety of pegylated interferon alpha-2a in epatients with myeloproliferative neoplasm

    Journal of Clinical Oncology, 2020

    Kaynak: ORCID

  12. Adverse event management in the TOURMALINE-MM3 study of post-transplant ixazomib maintenance in multiple myeloma

    Annals of Hematology, 2020

    DOI 10.1007/s00277-020-04149-5 PMID 32613281 6 atıf (Europe PMC) Açık erişimli tam metinKaynak: ORCID

  13. Allogeneic hematopoietic stem cell transplantation for primary myelofibrosis: A single-center experience

    Journal of Clinical Oncology, 2020

    DOI 10.1200/jco.2020.38.15_suppl.e19522 Kaynak: ORCID

  14. Apollo: Phase 3 Randomized Study of Subcutaneous Daratumumab Plus Pomalidomide and Dexamethasone (D-Pd) Versus Pomalidomide and Dexamethasone (Pd) Alone in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM)

    Blood, 2020

    DOI 10.1182/blood-2020-135874 50 atıf (OpenAlex) Kaynak: ORCID

  15. Are Autologous Stem Cell Transplants Still Required to Treat Myeloma in the Era of Novel Therapies? A Review from the Chronic Malignancies Working Party of the EBMT

    Biology of Blood and Marrow Transplantation, 2020

    DOI 10.1016/j.bbmt.2020.04.016 PMID 32417491 8 atıf (Europe PMC) Açık erişimli tam metinKaynak: ORCID

  16. Autologous haematopoietic stem-cell transplantation versus bortezomib–melphalan–prednisone, with or without bortezomib–lenalidomide–dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study

    The Lancet Haematology, 2020

    DOI 10.1016/s2352-3026(20)30099-5 PMID 32359506 306 atıf (Europe PMC) Açık erişimli tam metinKaynak: ORCID

  17. Clinical features associated with COVID-19 outcome in MM: First results from International Myeloma Society COVID-19 dataset

    medRxiv, 2020

    DOI 10.1101/2020.08.24.20177576 1 atıf (Europe PMC) Açık erişimli tam metinKaynak: ORCID

  18. Clinical features associated with COVID-19 outcome in multiple myeloma: First results from the International Myeloma Society data set

    Blood, 2020

    DOI 10.1182/blood.2020008150 PMID 33367546 162 atıf (Europe PMC) Açık erişimli tam metinKaynak: ORCID

  19. Comparison of Two Alkylating Agents Among Refractory Multiple Myeloma: Published and Our Retrospective Bendamustine Combination Experience with Melflufen As Single Agent

    Blood, 2020

    DOI 10.1182/blood-2020-137486 Kaynak: ORCID

  20. Conditioning with Bortezomib-MEL200 in Comparison to MEL200 Improves Survival Among Myeloma Patients IN≤PR Prior to Auto-HCT: A Study from the CMWP of the EBMT

    Bone Marrow Transplantation, 2020

    Kaynak: ORCID

  21. Consolidation Treatment with VRD Followed By Maintenance Therapy Versus Maintenance Alone in Newly Diagnosed, Transplant-Eligible Patients with Multiple Myeloma (MM): A Randomized Phase 3 Trial of the European Myeloma Network (EMN02/HO95)

    Blood, 2020

    DOI 10.1182/blood-2020-139337 5 atıf (OpenAlex) Kaynak: ORCID

  22. Daratumumab after Allogeneic Hematopoietic Stem Cell Transplantation in Multiple Myeloma: Safety and Efficacy. a Retrospective Study from the Cmwp EBMT

    Blood, 2020

    DOI 10.1182/blood-2020-138478 Kaynak: ORCID

  23. Daratumumab monotherapy for patients with intermediate-risk or high-risk smoldering multiple myeloma: a randomized, open-label, multicenter, phase 2 study (CENTAURUS)

    Leukemia, 2020

    DOI 10.1038/s41375-020-0718-z PMID 32024950 79 atıf (Europe PMC) Açık erişimli tam metinKaynak: ORCID

  24. Daratumumab, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma: Subgroup analysis of CASTOR based on cytogenetic risk

    Journal of Hematology and Oncology, 2020

    DOI 10.1186/s13045-020-00948-5 PMID 32819447 36 atıf (Europe PMC) Açık erişimli tam metinKaynak: ORCID

  25. Dihydroartemisinin Induces Growth Arrest and Overcomes Dexamethasone Resistance in Multiple Myeloma

    Frontiers in Oncology, 2020

    DOI 10.3389/fonc.2020.00767 PMID 32500030 17 atıf (Europe PMC) Açık erişimli tam metinKaynak: ORCID

  26. Drug Targeting of Genomic Instability in Multiple Myeloma

    Frontiers in Genetics, 2020

    DOI 10.3389/fgene.2020.00228 PMID 32373151 21 atıf (Europe PMC) Açık erişimli tam metinKaynak: ORCID

  27. Effect of Cyclophosphamide on Hemorrhagic Cystitis Following Haploidentical Related Compared to Matched Related/Unrelated Donor Hematopoietic Stem Cell Transplantation: A 7-Year Tertiary Center Analysis

    Biology of Blood and Marrow Transplantation, 2020

    DOI 10.1016/j.bbmt.2019.12.617 Açık erişimli tam metinKaynak: ORCID

  28. Effects of ABO incompatibility in allogeneic hematopoietic stem cell transplantation,Effets de l'incompatibilité ABO pour l'allogreffe de cellules souches hématopoïétiques

    Transfusion Clinique et Biologique, 2020

    DOI 10.1016/j.tracli.2020.06.008 PMID 32659269 10 atıf (Europe PMC) Kaynak: ORCID

  29. Efficacy and Safety of Carfilzomib, Dexamethasone, Daratumumab (KdD) Twice-Weekly at 56 mg/m2 and Once-Weekly at 70 mg/m2 in Relapsed or Refractory Multiple Myeloma (RRMM): Cross-Study Comparison of the CANDOR and EQUULEUS studies

    Clinical Lymphoma Myeloma and Leukemia, 2020

    Kaynak: ORCID

  30. Efficacy and Safety of the Panobinostat-Bortezomib-Dexamethasone Combination in Relapsed or Relapsed/Refractory Multiple Myeloma: Results from the Randomized Panorama 3 Study

    Blood, 2020

    DOI 10.1182/blood-2020-140697 4 atıf (OpenAlex) Kaynak: ORCID

  31. Efficacy and safety of carfilzomib, dexamethasone, daratumumab (KdD) twice-weekly at 56 mg/m2 and once-weekly at 70 mg/m2 in relapsed or refractory multiple myeloma (RRMM): Cross-study comparison of candor and MMY1001

    Journal of Clinical Oncology, 2020

    DOI 10.1200/jco.2020.38.15_suppl.8526 Kaynak: ORCID

  32. Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 study

    Blood Cancer Journal, 2020

    DOI 10.1038/s41408-020-00357-4 PMID 32887873 110 atıf (Europe PMC) Açık erişimli tam metinKaynak: ORCID

  33. Flamsa-based High-dose Sequential Conditioning Regimen followed by Allogeneic Hematopoietic Stem Cell Transplantation(ALLO-HSCT): Is It Effective in Patients with Primary Refractory or Relapsed Acute Leukemia?

    Bone Marrow Transplantation, 2020

    Kaynak: ORCID

  34. Health-Related Quality of Life in Patients with AL Amyloidosis Treated with Daratumumab, Bortezomib, Cyclophosphamide, and Dexamethasone: Results from the Phase 3 Andromeda Study

    Blood, 2020

    DOI 10.1182/blood-2020-139438 7 atıf (OpenAlex) Kaynak: ORCID

  35. Isatuximab for the treatment of relapsed/refractory multiple myeloma

    Expert Opinion on Biological Therapy, 2020

    DOI 10.1080/14712598.2021.1841747 PMID 33111607 33 atıf (Europe PMC) Açık erişimli tam metinKaynak: ORCID

  36. Ixazomib as postinduction maintenance for patients with newly diagnosed multiple myeloma not undergoing autologous stem cell transplantation: The phase III TOURMALINE-MM4 trial

    Journal of Clinical Oncology, 2020

    DOI 10.1200/jco.20.02060 PMID 33021870 64 atıf (Europe PMC) Açık erişimli tam metinKaynak: ORCID

  37. Ixazomib vs placebo maintenance for newly diagnosed multiple myeloma (NDMM) patients not undergoing autologous stem cell transplant (ASCT): The phase III TOURMALINE-MM4 trial

    Journal of Clinical Oncology, 2020

    DOI 10.1200/jco.2020.38.15_suppl.8527 5 atıf (OpenAlex) Kaynak: ORCID

  38. KIR Genotype and KIR Ligand Phenotypes That Improve the in Vitro Cord Blood or Autologous NK Cell Mediated Cytotoxicity Against Myeloma Marrow Plasma Cells

    Biology of Blood and Marrow Transplantation, 2020

    DOI 10.1016/j.bbmt.2019.12.395 Açık erişimli tam metinKaynak: ORCID

  39. Large Granular Lymphocytosis and Its Impact on Long Term Clinical Outcomes Following Allogeneic Hematopoietic Stem Cell Transplantation: 14-Year Follow-up Data

    Biology of Blood and Marrow Transplantation, 2020

    DOI 10.1016/j.bbmt.2019.12.405 1 atıf (OpenAlex) Açık erişimli tam metinKaynak: ORCID

  40. Pomalidomide, bortezomib, and dexamethasone (PVd) in lenalidomide (LEN)-pretreated relapsed refractory multiple myeloma: Subanalysis of patients with renal impairment in OPTIMISMM

    Journal of Clinical Oncology, 2020

    DOI 10.1200/jco.2020.38.15_suppl.e20562 2 atıf (OpenAlex) Kaynak: ORCID

  41. Post-Transplant Cyclophosphamide for Graft Vs Host Disease Prophylaxis in Multiple Myeloma Patients Who Underwent Allogeneic Hematopoietic Cell Transplantation: First Comparison By Donor Type; A Study from the Chronic Malignancies Working Party of the EBMT

    Blood, 2020

    DOI 10.1182/blood-2020-137789 1 atıf (OpenAlex) Açık erişimli tam metinKaynak: ORCID

  42. Prognostic scoring system after transplantation in myeloma: predicting early relapse

    British Journal of Haematology, 2020

    DOI 10.1111/bjh.16986 PMID 32712969 3 atıf (Europe PMC) Açık erişimli tam metinKaynak: ORCID

  43. Reduction in Absolute Involved Free Light Chain and Difference between Involved and Uninvolved Free Light Chain Is Associated with Prolonged Major Organ Deterioration Progression-Free Survival in Patients with Newly Diagnosed AL Amyloidosis Receiving Bortezomib, Cyclophosphamide, and Dexamethasone with or without Daratumumab: Results from Andromeda

    Blood, 2020

    DOI 10.1182/blood-2020-137582 16 atıf (OpenAlex) Kaynak: ORCID

  44. Role of Chimerism and flow-cytometric Monitoring of Measurable Residual Disease(MRD) after Allogeneic Hematopoietic Stem Cell Transplantation(Allo-HSCT) in Predicting Relapse in Acute Myeloid Leukemia(AML)

    Bone Marrow Transplantation, 2020

    Kaynak: ORCID

  45. The Influence of anti-thymocyte Globulin(ATG) on the Outcomes of Patients with AML W/wo Measurable Residual Disease(MRD) at the time of Unrelated Donor Transplantation

    Bone Marrow Transplantation, 2020

    Kaynak: ORCID

  46. Thyroid dysfunctions in adult patients after allogeneic hematopoietic stem cell transplantation

    Clinical Transplantation, 2020

    DOI 10.1111/ctr.14049 PMID 32713042 5 atıf (Europe PMC) Kaynak: ORCID

  47. Treatment of Thrombocytopenia after Allogeneic Stem Cell Transplantation with Eltrombopag

    Bone Marrow Transplantation, 2020

    Kaynak: ORCID

  48. Upfront Autologous Hematopoietic Stem-Cell Transplantation Improves Overall Survival in Comparison with Bortezomib-Based Intensification Therapy in Newly Diagnosed Multiple Myeloma: Long-Term Follow-up Analysis of the Randomized Phase 3 EMN02/HO95 Study

    Blood, 2020

    DOI 10.1182/blood-2020-137575 21 atıf (OpenAlex) Kaynak: ORCID

  49. β-catenin mutations in acute myeloid leukemia

    The Egyptian Journal of Haematology, 2020

    DOI 10.4103/ejh.ejh_54_19 1 atıf (OpenAlex) Kaynak: ORCID

  50. ISATUXIMAB PLUS POMALIDOMIDE AND DEXAMETHASONE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA AND SOFT-TISSUE PLASMACYTOMAS: ICARIA-MM SUBGROUP ANALYSIS

    Hematology Transfusion and Cell Therapy, 2020

    DOI 10.1016/j.htct.2020.10.440 7 atıf (OpenAlex) Açık erişimli tam metinKaynak: OpenAlex